[Comparative study of the antithrombotic effect of aspirin and Bay U3405, antagonist of a thromboxane A2 receptor].
The antithrombotic activity of aspirin (acetylsalicylic acid), inhibitor of the synthesis of thromboxane A2 was compared to that of Bay U3405, a thromboxane A2 receptor antagonist. A model of experimental thrombosis induced by laser in guinea pig mesenteric arteries was used. Aspirin exhibited a dose-dependent antithrombotic activity with and inhibitory effect of 70% at the high dose of 100 mg/kg while Bay U 3405 was efficient at the dose of 10 mg/kg with a percent of inhibition that did not exceed 55%. These results showed that: first, the inhibition of the activity of thromboxane A2 by an antagonist was not more important than that by aspirin and second, the thromboxane A2 way was well implicated in the thrombosis in the guinea pig, suggesting that this species was a good model for the study of the mechanisms using the prostaglandins way in arterial thrombosis.
Cissé-Thiam
M
M
Laboratoire de Bactériologie, CHU de Dakar.
Drouet
L
L
D000818:Animals; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D002227:Carbazoles / Q000008:administration & dosage / Q000494:pharmacology*; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006168:Guinea Pigs; D008297:Male; D008638:Mesenteric Arteries; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D017482:Receptors, Thromboxane / Q000037:antagonists & inhibitors*; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology*; D013927:Thrombosis / Q000188:drug therapy
D002227:Carbazoles; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D017482:Receptors, Thromboxane; D013449:Sulfonamides; C063119:ramatroban; D001241:Aspirin